Stock Price
32.38
Daily Change
-1.88%
Yearly
62.80%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,986.00 -87.00 -1.43% -21.90%
Arca Biopharma 1.98 -0.04 -1.98% -58.32%
Acadia Pharmaceuticals 20.94 -2.11 -9.15% -60.76%
Acorda Therapeutics 1.88 -0.28 -12.96% -76.41%
Amgen 233.83 -1.53 -0.65% -5.82%
Bayer 52.06 -0.76 -1.44% -1.79%
Brainstorm Cell Therapeutics 3.39 -0.16 -4.51% -35.92%
Biogen 233.81 -5.49 -2.29% -14.62%
Bristol-Myers Squibb 64.89 -0.04 -0.06% -2.77%
Capricor Therapeutics 3.02 -0.07 -2.27% -44.49%
Cytokinetics 32.38 -0.62 -1.88% 62.80%
Exelixis 17.38 -0.74 -4.08% -26.32%
Geron 1.10 -0.10 -8.33% -37.85%
Genocea Biosciences 1.03 0 0% -63.08%
Halozyme Therapeutics 34.13 -1.43 -4.02% -29.29%
Ionis Pharmaceuticals 30.12 -2.96 -8.95% -50.65%
Intra Cellular Therapies 40.34 -2.73 -6.34% 21.54%
Ligand Pharmaceuticals 116.80 -8.11 -6.49% -10.64%
Eli Lilly 247.07 2.95 1.21% 24.48%
Merck & Co 81.54 0.16 0.20% -1.98%
Novartis 82.10 -0.35 -0.42% -4.00%
Pfizer 54.11 -0.84 -1.53% 47.32%
Regeneron Pharmaceuticals 611.22 -4.02 -0.65% 14.48%
Roche Holding 364.90 -2.45 -0.67% 14.68%
Sanofi 92.06 -0.14 -0.15% 10.61%
Acceleron Pharma 178.75 -0.93 -0.52% 57.43%

Indexes Price Day Year
NASDAQ 14507 -386.86 -2.60% 9.92%
US2000 2096 -66.23 -3.06% -2.55%

Cytokinetics
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.